PEG modified polyethylene imine derivative and preparation method thereof

A technology of polyethyleneimine and polyethylene glycol, which is applied in the direction of medical preparations of non-active ingredients, pharmaceutical formulas, genetic material components, etc., can solve the problem of reducing non-specific reactions, reducing the aggregation of PEI/DNA complexes, and transfection Reduced activity and other issues, to achieve the effect of reducing cytotoxicity, improving transfection activity, and reducing cytotoxicity

Inactive Publication Date: 2013-09-04
XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that PEGylation of PEI can improve the biocompatibility of PEI, reduce toxicity, reduce the aggregation of PEI/DNA complexes, reduce the phagocytosis of com

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PEG modified polyethylene imine derivative and preparation method thereof
  • PEG modified polyethylene imine derivative and preparation method thereof
  • PEG modified polyethylene imine derivative and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The preparation of the PEI derivative (PEG-Bu) of embodiment 1 PEG modification

[0051] figure 1 It is a schematic diagram of the synthetic route of PEG-modified PEI derivatives, including the following steps:

[0052] (a) prepare PEI-Bu according to the method described in CN102443169A, carry out infrared and nuclear magnetic detection, the results are respectively as follows figure 1 with figure 2 As shown, the results showed that PEI-Bu was obtained;

[0053] (b) Dissolve PEI-Bu in sodium bicarbonate solution, then stir and shake at room temperature with methoxypolyethylene glycol-succinimide carbonate (mPEG-Sc) in a molar ratio of 3:1 Or shock reaction for 4 hours.

[0054] (c) Separation and purification, the product is dissolved with a small amount of ultrapure water and then placed in a dialysis bag with a molecular weight cut-off of 3500Da for dialysis for 48 hours. After the dialysis, the product is filtered with a 0.22 μm microporous membrane, and then t...

Embodiment 2

[0062] Preparation of the complex (Polyplex) synthesized by embodiment 2 PEG-Bu and plasmid

[0063] Weigh quantitative polymer PEG-Bu, add ultrapure water to make a 2mg / mL solution, then filter it with a 0.22μm sterile filter head, and dilute the concentration of luciferase (pGL3-Control) plasmid to 1mg / mL;

[0064] Configure complex solutions with different mass ratios, keep the concentration of the plasmid solution constant, and then dilute the concentration of the polymer solution according to the mass ratio of the polymer (PEG-Bu) to the plasmid, and keep the diluted polymer solution and plasmid solution Finally, the polymer solution was quickly added to the plasmid solution and mixed, and incubated at room temperature for 30-120 minutes, so that a series of complexes with a mass ratio were obtained, which could be used for further determination of physical and chemical properties.

[0065] The complex agarose gel electrophoresis: Prepare agarose solution with a mass ra...

Embodiment 3

[0073] The cytotoxicity test of embodiment 3PEG-Bu

[0074] Inoculate cells (BRL-3A, Hela), digest the cells, and dilute to a density of 5×10 4 -10×10 4 / mL cell suspension, add 100 μL to each well of a 96-well plate, and incubate overnight.

[0075] Dilute the 2 mg / mL high molecular weight DMEM solution into different concentration gradients with a final volume of 100 μL. The complexes synthesized by different mass ratios of PEG-Bu and plasmid were prepared.

[0076] After taking out the cells, remove the medium with serum, wash with 100 μL of PBS (phosphate) buffer, directly add the prepared polymer DMEM solution or complex to each cell well, add 100 μL to the negative control group Serum-free phenol red-free DMEM. After 4 hours, remove the culture medium and polymer solution, add 100 μL of serum-free phenol red-free medium to each well, and then add 25 μL of MTT solution (3-(4,5-dimethylthiazole-2) -2,5-diphenyltetrazolium bromide salt solution, the solution was prepar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a PEG (Poly Ethylene Glycol) modified polyethylene imine derivative, which is obtained by dissolving PEI-Bu in an alkaline solution, and reacting with methoxy polyethylene glycol-succinimide carbonic ester. The derivative has simple structure and is easy to synthesize; compared with conventional PEI-Bu, PEG modified PEG-Bu has higher transfection activity, lower cytoxicity, and better biocompatibility in various cells; compared with existing PEGylation PEI, PEGylation PEI-Bu not only can lower the cytoxicity, but also obviously improve the transfection activity; and PEG modified PEI is a carrier of efficient and harmfulless gene material, so as to be more suitable for the transport of the gene material, and in particular for transport therapeutic genes-high blood pressure related genes angiotensinogen (AGT) and short hair pin RNA (shRNA) to conduct gene silencing, so as to realize high blood pressure gene therapy.

Description

technical field [0001] The invention relates to a polyethyleneimine derivative modified by polyethylene glycol and its preparation method and application. Background technique [0002] Gene therapy is the introduction of exogenous genetic material (DNA or RNA) into cells to promote or inhibit the expression of specific proteins, or replace or repair problematic genes, so as to achieve the purpose of disease treatment. Gene therapy has encountered a series of technical bottlenecks during its development, one of the most important bottlenecks is the safe and effective delivery of genetic material in vivo. [0003] Currently commonly used gene delivery vectors can be divided into recombinant viral vectors and artificially synthesized vectors (ie non-viral vectors). Although viral vectors show high transfection efficiency, the mutation of the virus will cause potential risk of pathogenicity, and the surface components of the virus will cause the human immune response. At the sa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C08G81/00C08G73/04C08G65/48A61K47/34A61K48/00
Inventor 王玉强苏靖陈书艳
Owner XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap